EICHORPublic-registry site landscape for NCT04882124, “Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD”, a Pulmonary Disease, Chronic Obstructive study sponsored by Novartis Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04882124 (registry record) |
| Study title | Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD |
| Official title | A 12-week Randomized, participant-and Investigator-blinded, Placebo-controlled, Parallel Group Study to Explore the Efficacy, Pharmacodynamics, Safety, and Pharmacokinetics of Two Doses of Inhaled CSJ117 in Adults With Chronic Obstructive Pulmonary Disease (COPD) |
| Sponsor | Novartis Pharmaceuticals |
| Condition(s) | Pulmonary Disease, Chronic Obstructive |
| Phase | PHASE2 |
| Listed sites | 15 |
| Site countries | United States, Australia, Canada, Czechia, Hungary, Japan |
Patient-friendly overview of this study: eichor.com/study/NCT04882124.
Eichor generates a preliminary site-risk snapshot for NCT04882124 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
More from Novartis Pharmaceuticals
← Eichor home · All tracked trials · Pulmonary Disease, Chronic Obstructive studies · Weekly briefs
